Sugi Predict

Sugi Predict / Compounds / SCHEMBL2642650

SCHEMBL2642650

SCHEMBL2642650

CCS(=O)(=O)c1ccc([O])cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSIP1 O75475 2/20 0.61
▸ GAA P10253 1/20 0.60
▸ ALDH1A1 P00352 5/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ PLCG1 P19174 1/20 0.41
▸ JAK2 O60674 1/20 0.39
▸ CA2 P00918 1/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ HSD11B1 P28845 1/20 0.38
▸ PTGDR2 Q9Y5Y4 1/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ RORC P51449 1/20 0.37
▸ PTGS2 P35354 1/20 0.37
▸ KIF11 P52732 1/20 0.37
▸ POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10455034 0.89 PSIP1 (0.74) PSIP1GAAALDH1A1CYP3A4CYP2C9
SCHEMBL23351954 0.79 PSIP1 (0.61) PSIP1GAAALDH1A1CYP3A4CYP2C9
SCHEMBL86088 0.79 ALDH1A1 (0.67) PSIP1GAAALDH1A1CYP3A4CYP2C9
Fluoresone SCHEMBL24999 0.77 PSIP1 (0.58) PSIP1GAAALDH1A1CA2KMT2A
SCHEMBL5375 0.77 PLCG1 (0.70) PSIP1GAAALDH1A1CYP3A4CYP2C9
SCHEMBL6496100 0.77 PSIP1 (0.58) PSIP1GAAALDH1A1CYP3A4CYP2C9
SCHEMBL9908320 0.77 PSIP1 (0.68) PSIP1GAAALDH1A1CA2KMT2A
SCHEMBL1973873 0.77 GAA (0.95) PSIP1GAAALDH1A1CYP3A4CYP2C9
SCHEMBL1657371 0.77 CA2 (0.59) PSIP1GAACA2KMT2ALMNA
SCHEMBL23043593 0.77 PSIP1 (0.58) PSIP1GAAALDH1A1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522926-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2016-12-20 — — US claimed
US-20150119365-A1 NOVEL ACTIVATORS OF GLUCOKINASE CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-04-30 — — US claimed
EP-2185570-B1 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS INC (US) 2014-03-19 — — EP claimed
US-20110294758-A1 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. (US) 2011-12-01 — — US claimed
JP-2010536773-A — — 2010-12-02 — — JP claimed
EP-2185570-A2 NOVEL ACTIVATORS OF GLUCOKINASE Metabasis Therapeutics, Inc. (US) 2010-05-19 — — EP claimed
WO-2009023718-A2 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. (US) 2009-02-19 — — WO claimed
US-10174062-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2019-01-08 — — US disclosed
US-10005805-B2 — — 2018-06-26 — — US disclosed
US-20170096440-A1 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. 2017-04-06 — — US disclosed
US-9522926-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2016-12-20 — — US disclosed
US-20150119365-A1 NOVEL ACTIVATORS OF GLUCOKINASE CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-04-30 — — US disclosed
US-8940927-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2015-01-27 — — US disclosed
US-20100041660-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES MSD K.K. (JP) 2010-02-18 — — US disclosed
US-7629362-B2 2-pyridine carboxamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-12-08 — — US disclosed
WO-2009023718-A2 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. (US) 2009-02-19 — — WO disclosed
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative MSD K.K. (JP) 2008-03-20 — — US disclosed
US-20060258701-A1 Novel 2-pyridinecarboxamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-16 — — US disclosed
EP-1702919-A1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-09-20 — — EP disclosed
EP-1598349-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-11-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10005805-B2 — GCKR, GCK, HK1 PSIP1 2031/4885GAA 49/4885ALDH1A1 1843/4885
US-20150119365-A1 NOVEL ACTIVATORS OF GLUCOKINASE GCKR, GCK, HK1 PSIP1 2133/4885GAA 178/4885ALDH1A1 2389/4885
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative GCK, GCKR, HK1 PSIP1 3785/4885GAA 86/4885ALDH1A1 1188/4885
US-20110294758-A1 NOVEL ACTIVATORS OF GLUCOKINASE GCKR, GCK, HK1 PSIP1 2133/4885GAA 178/4885ALDH1A1 2389/4885
US-20170096440-A1 NOVEL ACTIVATORS OF GLUCOKINASE GCKR, GCK, HK1 PSIP1 2133/4885GAA 178/4885ALDH1A1 2389/4885
US-20060258701-A1 Novel 2-pyridinecarboxamide derivatives GCKR, GCK, HK2 PSIP1 3913/4885GAA 482/4885ALDH1A1 1249/4885
US-20100041660-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES GCKR, GCK, HK2 PSIP1 3906/4885GAA 481/4885ALDH1A1 1207/4885
US-10174062-B2 Activators of glucokinase GCKR, GCK, HK1 PSIP1 2069/4885GAA 140/4885ALDH1A1 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.